Priralfinamide is under clinical development by Newron Pharmaceuticals and currently in Phase II for Neuropathic Pain (Neuralgia). According to GlobalData, Phase II drugs for Neuropathic Pain (Neuralgia) have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Priralfinamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Smarter leaders trust GlobalData
Priralfinamide overview
Ralfinamide is under development for the treatment of rare neuropathic pain. The drug candidate is administered through oral route. Ralfinamide acts by targeting sodium channels, including Nav 1.7, N-type calcium channels and NMDA receptor. It was also under development for the inflammatory pain and low back pain.
Newron Pharmaceuticals overview
Newron Pharmaceuticals is a research-based biopharmaceutical company that focuses on the discovery, development, and commercialization of novel therapeutic drugs for the treatment of central nervous system disorders and pain. The company’s marketed product, Xadago (safinamide), is developed as an adjunctive therapy for any stage of Parkinson’s disease. Newton’s other products in the pipeline include ralfinamide for neuropathic pain; sarizotan for Rett syndrome; and Evenamide (NW-3509) for the treatment of schizophrenia. The company has development and commercialization collaborations with Zambon and Meiji Seika Pharma Co Ltd. It operates along with its subsidiaries in the UK, Switzerland, Sweden, and the US. Newron is headquartered in Bresso, Milan, Italy.
For a complete picture of Priralfinamide’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
